Monte Rosa Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Monte Rosa Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q2 2024.
  • Monte Rosa Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $252K, a 32.6% increase year-over-year.
  • Monte Rosa Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $483K, a 154% increase year-over-year.
  • Monte Rosa Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $338K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $483K $252K +$62K +32.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $421K $83K +$83K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $338K -$22K -$22K Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $360K $170K +$170K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $190K $190K +$190K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $0 $0 $0 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $0 $0 Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $0 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $0 Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.